Get the Stockscreener App
2.20
4.76%
-0.11
After Hours:
2.22
0.02
+0.91%
Grace Therapeutics Inc stock is traded at $2.20, with a volume of 11,361.
It is down -4.76% in the last 24 hours and down -16.98% over the past month.
See More
Previous Close:
$2.31
Open:
$2.23
24h Volume:
11,361
Relative Volume:
0.15
Market Cap:
$30.18M
Revenue:
-
Net Income/Loss:
$-11.61M
P/E Ratio:
-1.6994
EPS:
-1.2946
Net Cash Flow:
$-11.82M
1W Performance:
-3.08%
1M Performance:
-16.98%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.20
$2.3001
1-Week Range:
$2.20
$2.40
52-Week Range:
$2.07
$4.965
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.20 | 30.18M | 0 | -11.61M | -11.82M | -1.2946 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Aneurysmal Subarachnoid Hemorrhage Market to Reach New Heights - openPR.com
Aneurysmal Subarachnoid Hemorrhage Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre - Barchart.com
Grace Therapeutics secures up to $30 million financing - MSN
ASUS Introduces Ascent GX10 AI Supercomputer Powered by NVIDIA GB10 Grace Blackwell Superchip - Yahoo Finance
Cadence Accelerates AI-Driven Engineering Design and Science with NVIDIA Grace Blackwell - Yahoo Finance
Subarachnoid Hemorrhage Treatment Market Size in the 7MM - openPR
Acasti Pharma stock hits 52-week low at $2.12 amid challenges - Investing.com Australia
Acasti Pharma stock hits 52-week low at $2.12 amid challenges By Investing.com - Investing.com South Africa
Tesla’s fall from grace may have no equal, says JPMorgan: ‘We struggle to think of anything analogous’ - Yahoo Finance
The Inner Circle acknowledges, Grace Merrell Slezak as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - Yahoo Finance
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
Matinas BioPharma Lands Organovo Chairman, Pharma Veteran in Strategic Board Revamp - Stock Titan
Grace Therapeutics Reports Q3 Progress and Financial Results - TipRanks
Grace Therapeutics Files Form S-3 for Flexible Securities Offering - TipRanks
Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing shows - Marketscreener.com
Moderna, Inc. - Britannica
CORTCorcept Therapeutics Inc Latest Stock News & Market Updates - StockTitan
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
CORCEPT THERAPEUTICS INC SEC 10-K Report - TradingView
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Grace Therapeutics' Novel aSAH Treatment Impress Investors at Major Healthcare Conference? - StockTitan
Grace Therapeutics reports positive Phase 3 trial results for GTx-104 - MSN
GRCE: STRIVE-ON Results Reported - MSN
Corcept Therapeutics stock soars to all-time high of $62.34 - MSN
Grace Therapeutics’ (GRCE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright reiterates buy on Grace Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates buy on Grace Therapeutics stock - Investing.com India
Promising Potential of Grace Therapeutics’ GTX-104 Drives Buy Rating - TipRanks
Grace Therapeutics On Track For NDA Submission Of GTx-104 For Aneurysmal Subarachnoid Hemorrhage - Nasdaq
GRACE THERAPEUTICS Earnings Results: $GRCE Reports Quarterly Earnings - Nasdaq
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports Positive Phase 3 STRIVE-ON Trial Results for GTx-104 and Secures $30 Million in Financing; NDA Submission Expected by Mid-2025 - Nasdaq
Grace Therapeutics Inc. (GRCE) reports earnings - Quartz
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results - TradingView
Grace Reports Clinical Trial Victory and Major Cash Infusion in Latest Earnings - StockTitan
Grace Therapeutics, Inc. SEC 10-Q Report - TradingView
Grace Therapeutics secures up to $30 million financing By Investing.com - Investing.com Nigeria
Grace Therapeutics secures $15m for GTx-104 pre-commercial development - MSN
Grace therapeutics announces private placement financing of $30 million - MSN
Sector Update: Health Care Stocks Softer Late Afternoon -February 10, 2025 at 04:01 pm EST - Marketscreener.com
Sector Update: Health Care Stocks Softer Late Afternoon - TradingView
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):